Please provide your email address to receive an email when new articles are posted on . A 20-mg daily dose of ezetimibe yielded significantly greater reductions in total and LDL cholesterol among ...

FDA Approves New Labeling for VYTORIN to Include Data From SHARP Showing That VYTORIN Effectively Lowered LDL Cholesterol in These Patients, With Fewer Major Vascular Events in Patients Taking VYTORIN ...

-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at ...

(HealthDay News) — For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone, according to a study published ...

Please provide your email address to receive an email when new articles are posted on . ATLANTA – Patients assigned to combination therapy with rosuvastatin plus ezetimibe experienced greater ...

NEW ORLEANS, November 8, 2004 – Results from a new study showed that coadministration of ZETIA® (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density ...

% differences compared with placebo or indicated statin are based on differences of individual least square means for LDL-C, HDL-C, non-HDL-C and apoB, and on differences of individual medians or ...

Ezetimibe/simvastatin (Vytorin) was associated with an increased incidence of cancer, based on a secondary analysis of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) randomized trial (N Engl ...

NAARDEN, Netherlands--(BUSINESS WIRE)--NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases, today ...

Obicetrapib, a Lazarus-like cholesteryl ester transfer protein (CETP) inhibitor currently on its second life, checked another box in its development program with investigators showing the drug could ...